Le Lézard
Classified in: Health, Science and technology

Center Point Bio-Tech Signs National Distribution Agreement


LAS VEGAS, NV / ACCESSWIRE / May 20, 2024 / In anticipation of commercial launch of the AlphaION Point of Care diagnostic platform, Center Point Bio-Tech, LLC ("CP Bio") entered into a non-exclusive distribution agreement with a well-known and highly respected veterinary distributor with over 60 years of sales excellence and logistics expertise to sell and distribute products to veterinary hospitals.

"Center Point Bio-Tech's development of AlphaION continues on schedule and we anticipate an on time launch by the end of 2024," said Tim Baum, founder and CEO of Center Point Bio-Tech. "We expect to place additional beta units in Q2 to finalize manufacturing specifications in Q3. Given our accelerated pace of product development, we are aggressively implementing our strategy of building Center Point Bio-Tech as a market leader in the development of disruptive technologies for diagnosing and managing disease in animals."

"The interest our distribution partners have shown in AlphaION confirms the commercial potential of Center Point Bio-Tech's new and disruptive technology," said Dr. Bonnie Bragdon, Chief Commercial Officer. "Signing a second distribution partner at this point in product development, sets the stage for a successful and aggressive product launch. We will continue to carefully refine our AlphaION launch strategy and selectively add distribution partners who serve our shared customers with excellence."

AlphaION is a novel, patent pending veterinary diagnostic system for use in veterinary practices. AlphaION is revolutionary in its use of new technologies to bring more testing options to veterinary practice and its use of lab automation and artificial intelligence to improve hospital workflow. AlphaION is now available for purchase with an anticipated delivery date in Q4 2024.

Equipped with AlphaION, veterinarians will be able to diagnose and manage complex internal medicine and infectious disease cases almost completely at the point of care for companion, production, and exotic animals. AlphaION is simple enough to operate at the point of care and powerful enough to meet the needs of veterinarians across many specialties. AlphaION is simply powerful.

About Center Point Bio-Tech

Center Point Bio-Tech specializes in bringing unique, cost-effective, and innovative diagnostic products to veterinary practice. Center Point Bio-Tech is dedicated to quality and brings products to market only after extensive testing and research. Deep knowledge of veterinary hospital and lab operations allows Center Point Bio-Tech to deliver value and provide solutions for veterinary offices of all sizes. A dedicated team of veterinary industry professionals works to seamlessly integrate Center Point Bio-Tech products into veterinary practices caring for companion, production, and exotic animals. Learn more about Center Point Bio-Tech and ALphaION at www.cpbio.com AlphaION is a trademark of Center Point Bio-Tech.

Contact Information:

Paul Soth
Chief Financial Officer
800-640-7780

Tim Baum
CEO & Founder
800-640-7780

Bonnie Bragdon
Chief Commercial Officer
[email protected]
800-640-7780

Related Files

Press release Distribution General 5.20.2024

SOURCE: Center Point Bio-Tech

.

View the original press release on newswire.com.


These press releases may also interest you

at 18:05
New Blood Test Predicts Recurrence of Breast Cancer, Months or Even Years Before Relapse
A new type of blood test can predict the recurrence of breast cancer in high-risk patients, months or even years before they relapse, research has shown. A team from The Institute of Cancer Research, London, used an ultra-sensitive liquid biopsy to...

at 17:35
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
Genmab A/S today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with certain types of follicular lymphoma...

at 14:35
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
Positive results from the LAURA Phase III trial showed AstraZeneca's TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable,...

at 12:35
CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated with Visugromab/Nivolumab Combination
CatalYm today announced positive new follow-up results from its ongoing "GDFATHER" Phase 1/2a trial (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 1/2a) (NCT04725474) in an oral presentation at the American Society of Clinical...

at 11:35
KFSHRC Successfully Treats Severe Case of "Xanthoma" After 26 Years of Suffering
In an era where healthcare innovation is paramount, KFSHRC Jeddah has made headway in the treatment of severe Xanthoma through the deployment of a modified plasma exchange protocol. This milestone underscores KFSHRC's position as a trailblazer in...

at 11:00
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
GSK plc (LSE/NYSE: GSK) today announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating belantamab mafodotin, in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care,...

More news about Health...


News published on and distributed by: